Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency

NCT05526066 is registered in ClinicalTrials.gov with Arcturus Therapeutics, Inc. as lead sponsor.

NCT NCT05526066
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05526066 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Nested Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARCT-810 in Adolescent and Adult Participants With Ornithine Transcarbamylase Deficiency
Lead sponsor
Arcturus Therapeutics, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 17, 2022
Completion date
October 31, 2024
Enrollment
8 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

ornithine transcarbamylase deficiency, otc deficiency, otcd